Downgrade Alert for Fresenius Medical Care (FMS)
Fresenius Medical Care (NYSE:FMS) was downgraded from Buy to Hold at Societe Generale today. The stock closed yesterday at $41.04 on volume of 136,000 shares, below average daily volume of 200,000.
Potential upside of 0.0% exists for Fresenius Medical Care, based on a current level of $0.00 and analysts' average consensus price target of $43.93. The stock should find initial resistance at its 200-day moving average (MA) of $40.02 and further resistance at its 50-day MA of $42.47.
Over the past year, Fresenius Medical Carehas traded in a range of $0.00 to $44.34 and are now at $0.00. Over the last five market days, the 200-day moving average (MA) has gone up 0.2% while the 50-day MA has declined 0.2%.
Fresenius Medical Care AG & Co. KGaA offers kidney dialysis services and manufactures and distributes equipment and products used in the treatment of dialysis patients. The Company also offers clinical laboratory testing and diagnostic testing services and provides home infusion, respiratory therapy, ultrasound, and echo-cardiography. Fresenius operates worldwide.
SmarTrend is monitoring the recent change of momentum in Fresenius Medical Care. Please refer to our Company Overview for the results of our proprietary technical indicators that have been scanning shares of Fresenius Medical Care in search of a potential trend change.
Keywords: analyst upgrades/downgrades fresenius medical care